---
title: "Ona Therapeutics's $86.6M Series B: Barcelona's ADC Cancer Bet"
description: "Barcelona biopharma Ona Therapeutics closed an oversubscribed $86.6M Series B in June 2026 to advance first-in-class antibody-drug conjugates for resistant cancers."
date: 2026-06-03T00:00:00.000Z
tags: ["2026-vc-news", "startup-funding", "venture-capital", "healthtech", "europe-vc"]
source: https://venturecapitaltracker.com/2026-ona-therapeutics-86m-series-b-adc
---

# Ona Therapeutics's $86.6M Series B: Barcelona's ADC Cancer Bet

> Barcelona biopharma Ona Therapeutics closed an oversubscribed $86.6M Series B in June 2026 to advance first-in-class antibody-drug conjugates for resistant cancers.

Ona Therapeutics's **oversubscribed $86.6M Series B** in June 2026 is European biotech at its most fundable: **differentiated, validated science** aimed at a hard clinical problem.

### The problem this startup is attacking
Treatment-resistant cancers evade existing therapies. Ona develops first-in-class antibody-drug conjugates (ADCs) — targeted payloads designed to kill cancer cells that current drugs can't reach.

### Why this is a live problem now
- ADCs are one of oncology's hottest modalities.
- Treatment resistance is a major unmet need.
- The reopening exit market improves European biotech funding appetite.

### Competitive map
- Global ADC developers and big-pharma oncology pipelines.
- Other European clinical-stage biotechs.

### Market signal (the number to remember)
- **Oversubscribed $86.6M Series B** — strong demand for a Barcelona biotech signals investor appetite for validated, differentiated oncology science.

### Practical takeaway (operator + investor)
Ona shows European biotech can raise robustly on **first-in-class science and clear clinical rationale**. Founders should lead with mechanism and preclinical/clinical data; investors should keep European life sciences in the mix.

### Sources
1. Startuprise (Ona Therapeutics $86.6M Series B): https://startuprise.co.uk/top-funding-wrap-of-the-week-01-june-05-june-2026/